Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effectiveness of Intravitreal Avastin Injection for CRVO

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01678248
Recruitment Status : Unknown
Verified August 2012 by Ziv Hospital.
Recruitment status was:  Recruiting
First Posted : September 3, 2012
Last Update Posted : September 3, 2012
Sponsor:
Information provided by (Responsible Party):
Ziv Hospital

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
to determine the effectivness of intravitreal avastin injection on visual acuity on people that suffer from central retinal vein occlusion

Condition or disease
Central Retinal Vein Occlusion

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 68 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: The Effectiveness of Intravitreal Avastin Injection for CRVO
Study Start Date : January 2006
Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
patients who suffer from CRVO and were injected by bevazicumab intravitrealy
Criteria

Inclusion Criteria:

  • patients above 18 years old
  • suffer from CRVO
  • maximal visual acuity 6/15

Exclusion Criteria:

  • VA of LP
  • retinal disease other than CRVO
  • incomplete medical record
  • follow up less than 6 months
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01678248


Contacts
Layout table for location contacts
Contact: Joseph pikkel, M.D 972508434206 pikel.y@ziv.health.gov.il
Contact: Otzem Chassid, M.D 972506266059 otzem.c@ziv.health.gov.il

Locations
Layout table for location information
Israel
Ziv Medical Center Recruiting
Safed, Israel, 13100
Contact: Otzem Chassid, M.D       otzem.c@ziv.health.gov.il   
Principal Investigator: Joseph Pikkel, M.D         
Sponsors and Collaborators
Ziv Hospital
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for additonal information
Responsible Party: Ziv Hospital
ClinicalTrials.gov Identifier: NCT01678248    
Other Study ID Numbers: 0048-12-ZIV
First Posted: September 3, 2012    Key Record Dates
Last Update Posted: September 3, 2012
Last Verified: August 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Retinal Vein Occlusion
Retinal Diseases
Eye Diseases
Venous Thrombosis
Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
 Bevacizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors